Clinical Pharmacogenetic Model to Predict Response of MTX Monotherapy in Patients with Established Rheumatoid Arthritis After DMARD Failure

• Korpela M , LaasonenL, HannonenP et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 50(7) , 2072–2081 (2004).
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP , de Vries-Bouwstra JK, Allaart CF et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med.146(6) , 406–415 (2007).
   PubMed Web of Science ®Google Scholar
• van der Kooij SM , Goekoop-RuitermanYP, de Vries-Bouwstra JK et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis. Ann. Rheum. Dis.68 , 914–921 (2009).
   PubMed Web of Science ®Google Scholar
• Saunders SA , CapellHA, StirlingA. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum.58(5) , 1310–1317 (2008).
   PubMedGoogle Scholar
• Klareskog L , van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet363(9410) , 675–681 (2004).
   PubMed Web of Science ®Google Scholar
• van der Heijde D , KlareskogL, Rodriguez-ValverdeV et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54(4) , 1063–1074 (2006).
   PubMed Web of Science ®Google Scholar
• Wessels JA , van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum.56(6) , 1765–1775 (2007).
   PubMed Web of Science ®Google Scholar
• Barrera P , van der Maas A, van Ede AE et al. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-α antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatol. (Oxford).41(4) , 430–439 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson JJ , WellsG, VerhoevenAC, FelsonDT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum.43(1) , 22–29 (2000).
   PubMed Web of Science ®Google Scholar
• Welsing PM , van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. J. Rheumatol. Suppl.69 , 14–21 (2004).
   PubMedGoogle Scholar
• Van der Heijde DM , van‘t Hof MA, van Riel PL et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann. Rheum. Dis.49(11) , 916–920 (1990).
   PubMed Web of Science ®Google Scholar
• Van Gestel AM , PrevooML, van‘t Hof MA et al. Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against rheumatism criteria. Arthritis Rheum.39(1) , 34–40 (1996).
   PubMed Web of Science ®Google Scholar
• Bleeker SE , MollHA, SteyerbergEW et al. External validation is necessary in prediction research: a clinical example. J. Clin. Epidemiol. 56(9) , 826–832 (2003).
   PubMed Web of Science ®Google Scholar
• Gricor C , CapellH, StirlingA et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430) , 263–269 (2004).
   PubMed Web of Science ®Google Scholar
• Visser K , KatchamartW, LozaE et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis. 68 , 1086–1093 (2009).
   PubMed Web of Science ®Google Scholar
• Bijlsma JW , WeinblattME. Optimal use of methotrexate: the advantages of tight control. Ann. Rheum. Dis.66(11) , 1409–1410 (2007).
   PubMed Web of Science ®Google Scholar
• Kapral T , StammT, MacholdKP et al. Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. Arthritis Res. Ther. 8(2) , R46 (2006).
   PubMed Web of Science ®Google Scholar
• Visser K , Van der Heijde DM. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann. Rheum. Dis.68 , 1094–1099 (2009).
   PubMed Web of Science ®Google Scholar
• Van der Kooij SM , de Vries-Bouwstra JK, Goekoop-Ruiterman YP et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann. Rheum. Dis.66(10) , 1356–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Wessels JA , KooloosWM, De Jonge R et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum.54(9) , 2830–2839 (2006).
   PubMedGoogle Scholar
• Colhoun HM , McKeiguePM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet361(9360) , 865–872 (2003).
   PubMed Web of Science ®Google Scholar
• Spector TD , AhmadiKR, ValdesAM. When is a replication not a replication? Or how to spot a good genetic association study. Arthritis Rheum.54(4) , 1051–1054 (2006).
   PubMedGoogle Scholar

▪ Website

• PubMed. www.ncbi.nlm.nih.gov/sites/entrez
   Google Scholar